This is a preview of subscription content, log in via an institution to check access.
Notes
absolute neutrophil count
incremental cost-effectiveness ratios
Reference
Perrier L, et al. Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma : An Economic Evaluation of the PALM Trial. Applied Health Economics and Health Policy : 23 Feb 2013. Available from: URL: http://dx.doi.org/10.1007/s40258-013-0011-7
Rights and permissions
About this article
Cite this article
Pegfilgrastim dominates filgrastim in haematological malignancies. PharmacoEcon Outcomes News 673, 5 (2013). https://doi.org/10.1007/s40274-013-0203-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0203-2